Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
07 November 2023 - 2:12AM
Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a
clinical-stage TechBio company specializing in the development of
AI-Immunology™ powered vaccines, is hosting an online webinar
featuring Key Opinion Leader (KOL) and study’s Principal
Investigator (PI), Professor Adnan Khattak. The webinar will take
place on November 8 at 11:30 a.m. EST.
In this 30-minute-long event, Professor Khattak
will set the scene by introducing participants to the medical field
of malignant melanoma and the need that Evaxion’s personalized
cancer vaccines are trying to meet. After summarizing the promising
results reported in the EVX-01 Phase 1 clinical trial, Adnan will
dive into Evaxion’s latest EVX-01 Phase 2 clinical update and how
these appear to confirm the benefits previously observed for this
innovative immunotherapy. In the end, a Q&A session will be
held for anyone who wants to learn more about this study and its
underlying technology.
Evaxion’s Chief Executive Officer, Christian
Kanstrup, commented: “‘This latest clinical update stands as a
testament to Evaxion’s unwavering dedication to transforming
patients’ lives through innovative and targeted immunotherapies.
Despite initial skepticism surrounding our pioneering work in
personalized cancer vaccines, we are now reaping consistently
positive outcomes that we believe hold the promise to change the
lives of melanoma patients.” Reflecting on how these results may
impact the oncology field in the near future, Christian added, “‘We
firmly believe that our AI-Immunology™ platform has the potential
to spearhead a revolution in immuno-oncology, extending far beyond
melanoma and positively touching the lives of countless
individuals.”
To learn more about the clinical impact of
Evaxion’s innovative EVX-01 vaccine and gain understanding of how
personalized cancer vaccines can revolutionize the field of
immuno-oncology, please register by following this link.
About EVX-01 Phase 1 Clinical TrialThe
open-label, single-arm, single-center Phase 1 study was conducted
in collaboration with DTU, SSI, the Center for Genomic Medicine at
Rigshospitalet, and CCIT-DK. The study aimed to assess the safety
and efficacy of the EVX-01 vaccine in combination with anti-PD1
(pembrolizumab or Nivolumab) in patients with metastatic melanoma.
The design consisted of multiple 15-27mer peptides comprising one
or more patient-specific neoantigens formulated with the novel
liposomal adjuvant CAF®09b to potentiate immune responses. The
primary objective was to evaluate the safety and tolerability of
the combination of EVX-01 and a checkpoint inhibitor. Additional
information can be accessed under clinical trial ID
NCT03715985.
About EVX-01 Phase 2 Clinical
Trial EVX-01 is Evaxion’s lead clinical asset
and constitutes a peptide-based personalized cancer vaccine. The
Phase 2 clinical study is a self-sponsored open-label, single-arm,
multi-center trial carried out in collaboration with Merck Sharp
& Dohme LLC, and together with leading principal investigators
and research centers from Italy and Australia aims at evaluating
the efficacy and safety of EVX-01 vaccination in combination with
anti-PD1 treatment (pembrolizumab) in treatment-naive patients with
metastatic or unresectable malignant stage III or IV melanoma. More
information can be accessed under clinical trial ID
NCT05309421.
About EVAXION Evaxion
Biotech A/S is a pioneering TechBio company based upon its AI
platform: AI-Immunology™. Evaxion’s proprietary and scalable AI
prediction models harness the power of artificial intelligence to
decode the human immune system and develop novel immunotherapies
for cancer, bacterial diseases, and viral infections. Based upon
AI-Immunology™, Evaxion has developed a clinical-stage oncology
pipeline of novel personalized vaccines and a preclinical
infectious disease pipeline in bacterial and viral diseases with
high unmet medical needs. Evaxion is committed to transforming
patients’ lives by providing innovative and targeted treatment
options. For more information about Evaxion and its groundbreaking
AI-Immunology™ platform and vaccine pipeline, please visit our
website.
Forward-Looking
Statement This announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The words “target,” “believe,” “expect,”
“hope,” “aim,” “intend,” “may,” “might,” “anticipate,”
“contemplate,” “continue,” “estimate,” “plan,” “potential,”
“predict,” “project,” “will,” “can have,” “likely,” “should,”
“would,” “could,” and other words and terms of similar
meaning identify forward-looking statements. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various factors, including, but not
limited to, risks related to: our financial condition and need for
additional capital; our development work; cost and success of our
product development activities and preclinical and clinical trials;
commercializing any approved pharmaceutical product developed using
our AI platform technology, including the rate and degree of market
acceptance of our product candidates; our dependence on third
parties including for conduct of clinical testing and product
manufacture; our inability to enter into partnerships; government
regulation; protection of our intellectual property rights;
employee matters and managing growth; our ADSs and ordinary
shares, the impact of international economic, political, legal,
compliance, social and business factors, including inflation, and
the effects on our business from the worldwide ongoing COVID-19
pandemic and the ongoing conflict in the region
surrounding Ukraine and Russia and the Middle East; and other
uncertainties affecting our business operations and financial
condition. For a further discussion of these risks, please refer to
the risk factors included in our most recent Annual Report on Form
20-F and other filings with the U.S. Securities and Exchange
Commission (SEC), which are available
at www.sec.gov. We do not assume any obligation to
update any forward-looking statements except as required by
law.
Contact Information
Evaxion Biotech A/S
Christian Kanstrup
Chief Executive Officer
cka@evaxion-biotech.com
Source: Evaxion Biotech
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Apr 2024 to May 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From May 2023 to May 2024